On 18 Nov 2025, Sequent Scientific’s shares touched an intraday peak of Rs.249.15, marking the highest price level recorded in the past year. This new high comes after the stock demonstrated consistent gains over the last two trading sessions, delivering a cumulative return of 7.9% during this period. The day’s price movement saw the stock outperform its sector by 6.93%, highlighting relative strength within the Pharmaceuticals & Biotechnology space.
Technical indicators reinforce this positive momentum, with Sequent Scientific trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Such positioning typically signals sustained buying interest and a robust trend in the stock’s price action.
From struggle to strength! This small-cap from Pharmaceuticals & Biotechnology is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- Early turnaround signals
- Explosive growth potential
- Pharmaceuticals & Biotechnology recovery play
Position for Explosive Growth →
Over the past year, Sequent Scientific’s stock price has recorded a gain of 30.92%, significantly outpacing the broader Sensex index, which has shown a 9.72% increase over the same period. This relative outperformance highlights the stock’s resilience and appeal within its sector. The 52-week low for the stock was Rs.111, indicating a substantial price range and recovery over the last twelve months.
In contrast, the Sensex index experienced a volatile session today, opening 91.42 points higher but eventually declining by 185.60 points to trade at 84,856.77, down 0.11%. Despite this, the Sensex remains close to its own 52-week high of 85,290.06, currently just 0.51% away. The index is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, suggesting an overall bullish trend in the broader market.
Sequent Scientific’s market capitalisation grade stands at 3, reflecting its mid-tier valuation within the Pharmaceuticals & Biotechnology sector. The company’s mojo score is 57.0, with a mojo grade currently at Hold following an adjustment in evaluation from a previous Sell grade dated 2 Sep 2025. The trigger for the recent score revision was the attainment of the 52-week high on 18 Nov 2025, signalling a noteworthy shift in the stock’s performance metrics.
Holding Sequent Scientific from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- Peer comparison ready
- Superior options identified
- Cross market-cap analysis
The stock’s recent performance is supported by a combination of sectoral dynamics and company-specific factors. The Pharmaceuticals & Biotechnology sector continues to exhibit resilience, with several stocks trading above their respective moving averages, signalling sustained investor interest in the space. Sequent Scientific’s ability to maintain gains above multiple moving averages further emphasises its current strength relative to peers.
Today’s 6.89% day change in Sequent Scientific’s share price is a significant contributor to its new 52-week high, reflecting strong buying momentum. The stock’s consecutive gains over the last two days have contributed to this upward movement, reinforcing the positive trend observed in recent weeks.
While the broader market showed some volatility, Sequent Scientific’s stock demonstrated relative stability and strength. This divergence from the Sensex’s intraday decline highlights the stock’s capacity to hold ground amid fluctuating market conditions.
In summary, Sequent Scientific’s achievement of a new 52-week high at Rs.249.15 marks a key milestone in its price journey. The stock’s performance over the past year, combined with its current technical positioning and sectoral context, provides a comprehensive picture of its recent momentum. Investors and market participants can observe these factual developments as part of the ongoing market narrative surrounding this Pharmaceuticals & Biotechnology company.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
